睿知中国疾病研究地图
候选清单0

上海上海交通大学医学院

上海市胸科医院

Shanghai Chest Hospital

在本站收录的 53 种疾病中,这家医院列在其中 3 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

上海市胸科医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma40 篇牵头论文牵头 12 项开放试验
  2. 骨肉瘤Osteosarcoma0 篇牵头论文
  3. 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文

未列出的收录疾病:鼻咽癌、肝细胞癌、胃癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 40 篇,占 1.4%。

牵头论文
40
2021–2025 年
牵头试验
20
任何状态,ClinicalTrials.gov
牵头的开放试验
12
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 5520222023: 8820232024: 8820242025: 11112025

上海有 18 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 14

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
    分期
    II期
    开始
    2026-07
    登记号
    NCT07811752

    年龄 18 岁 至 未注明(登记的条件)

    牵头:上海市胸科医院上海

  2. 正在招募
    Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
    分期
    II期
    开始
    2024-06
    登记号
    NCT06385730

    年龄 76 岁 至 未注明(登记的条件)

    牵头:上海市胸科医院上海

  3. 正在招募
    A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
    分期
    II期
    开始
    2024-11
    登记号
    NCT06709417

    年龄 20 岁 至 75 岁(登记的条件)

    牵头:上海市胸科医院上海

  4. 正在招募
    Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2023-01
    登记号
    NCT05978193

    年龄 18 岁 至 未注明(登记的条件)

    牵头:上海市胸科医院;另有 1 家列出的医院为研究中心上海

  5. 正在招募
    Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2023-09
    登记号
    NCT06056336

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海市胸科医院上海

  6. 正在招募
    Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
    分期
    I/II期
    开始
    2023-01
    登记号
    NCT06173986

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海市胸科医院上海

  7. 正在招募
    Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
    分期
    III期
    开始
    2019-09
    登记号
    NCT04135664

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海市胸科医院;另有 5 家列出的医院为研究中心上海、南昌、天津

  8. 即将招募
    SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy
    分期
    II期
    开始
    2026-03
    登记号
    NCT07524374

    年龄 18 岁 至 未注明(登记的条件)

    牵头:上海市胸科医院上海

  9. 即将招募
    Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
    分期
    II期
    开始
    2025-07
    登记号
    NCT06861894

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海市胸科医院上海

  10. 即将招募
    RAE Versus MIE in Patients With Esophageal Cancer After Neoadjuvant Therapy
    分期
    不分期
    开始
    2024-01
    登记号
    NCT06012214

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海市胸科医院上海

  11. 即将招募
    Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
    分期
    II期
    开始
    2023-12
    登记号
    NCT06178211

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海市胸科医院上海

  12. 邀请入组
    Infiltration Pattern of Locally Advanced ESCC
    分期
    未注明
    开始
    2025-10
    登记号
    NCT07567716

    年龄未注明(登记的条件)

    牵头:上海市胸科医院上海

  13. 正在招募
    A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
    分期
    I/II期
    开始
    2023-05
    登记号
    NCT05319730

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、北京、厦门、合肥、新乡、杭州、郑州

  14. 即将招募
    Safety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma
    分期
    不分期
    开始
    2024-12
    登记号
    NCT06756841

    年龄 20 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗手术放疗
论文中的科室放疗科病理/检验科
牵头的论文40
  1. Adjuvant immunotherapy for esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy: a multicenter real-world study.2026International journal of surgery (London, England)免费全文
  2. LAMP1 enhances DNA-PKcs-mediated AKT phosphorylation and VEGFC secretion to promote lymph node metastasis in esophageal squamous cell carcinoma.2026Oncogene
  3. Lymph node dissection in neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter real-world study.2026The Journal of thoracic and cardiovascular surgery
  4. The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 042025Annals of medicine免费全文
  5. Prognosis of Robot-Assisted Esophagectomy with Thoracic Duct Resection in Esophageal Squamous Cell Carcinoma.2025Annals of surgical oncology
  6. PPDPF promotes esophageal squamous cell carcinoma progression by blocking PCCA binding to PCCB and inhibiting methionine catabolism.2025Cancer letters
  7. ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma.2025Cell reports. Medicine免费全文
  8. Neoadjuvant Immuno-Chemotherapy Versus Neoadjuvant Chemoradiotherapy in Locally Advanced Oesophageal Squamous Cell Carcinoma.2025European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  9. Radiotherapy as an organ-preserving alternative to surgery in patients with locally advanced esophageal squamous cell carcinoma achieving major pathologic response after induction immunochemotherapy.2025International journal of cancer
  10. Prognostic value of middle paraesophageal lymph node metastasis in patients with pathologic N+ esophageal squamous cell carcinoma.2025International journal of surgery (London, England)免费全文
  11. Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma.2025JAMA surgery免费全文
  12. Detecting residual disease after neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: The prospective multicentre preSINO trial.2025The British journal of surgery免费全文
  13. A pathologic classification approach in esophageal squamous cell carcinoma following neoadjuvant immunochemotherapy: Distinguishing postoperative outcomes and exploring the potential benefit of adjuvant therapy.2025The Journal of thoracic and cardiovascular surgery
  14. Neoadjuvant Chemoimmunotherapy Combined With Node-Sparing Radiotherapy for Clinical T3N+ Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Single-Arm, Phase II Study (CINSREC Trial).2025Thoracic cancer免费全文
  15. Postoperative tumor bed radiation versus T-shaped field radiation in the treatment of locally advanced thoracic esophageal squamous cell carcinoma: a phase IIb multicenter randomized controlled trial.2024BMC medicineRCT免费全文
  16. Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma.2024Biology direct免费全文
  17. MFAP2 upregulation promotes ESCC metastasis via FAK-AKT signaling pathway.2024FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  18. Propensity-matched study on locally advanced esophageal cancer: surgery versus post-operative radiotherapy.2024Radiation oncology (London, England)免费全文
  19. Occurrence and recovery of vocal cord paralysis after minimally invasive McKeown esophagectomy, risk factors, and clinical outcome.2024Surgery
  20. Multiregion exome sequencing indicates a monoclonal origin of esophageal spindle-cell squamous cell carcinoma.2024The Journal of pathology
  21. Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study.2024The Journal of thoracic and cardiovascular surgery
  22. Homologous recombination deficiency score is an independent prognostic factor in esophageal squamous cell carcinoma.2024The journal of pathology. Clinical research免费全文
  23. Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.2023Annals of surgeryRCT
  24. Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial).2023BMC cancer免费全文
  25. Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma.2023Cancer cell
  26. Robot-assisted versus thoracolaparoscopic oesophagectomy for locally advanced oesophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  27. Phase II multicenter trial: first-line immunochemotherapy with or without radiotherapy in metastatic esophageal squamous cell cancer (SCR-ESCC-01).2023Future oncology (London, England)
  28. PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma.2023Journal of biomedical science免费全文
  29. Prognostic Value of Combination of Lymphocyte-to-Monocyte-Ratio and CYFRA 21-1 in Esophageal Squamous Cell Carcinoma.2023World journal of surgery
  30. Salvage Esophagectomy After Definitive Chemoradiotherapy for Squamous Cell Esophageal Cancer: A Propensity Score Matching Study in a High-Volume Center.2023World journal of surgery
  31. Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma: Early Results of a Multicenter Randomized Controlled Trial: the RAMIE Trial.2022Annals of surgeryRCT
  32. Occurrence and Prognostic Value of Perineural Invasion in Esophageal Squamous Cell Cancer: A Retrospective Study.2022Annals of surgical oncology
  33. Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study).2022BMC cancerRCT免费全文
  34. Impact of body mass index on perioperative and oncological outcomes in elderly patients undergoing minimally invasive McKeown esophagectomy for esophageal squamous cell carcinoma.2022Cancer medicine免费全文
  35. Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations.2022Signal transduction and targeted therapy免费全文
  36. Additional Esophagectomy Following Noncurative Endoscopic Resection for Early Esophageal Squamous Cell Carcinoma: A Multicenter Retrospective Study.2021Annals of surgical oncology
  37. ASO Author Reflections: Is Esophagectomy Necessary after Noncurative Endoscopic Resection for Early Esophageal Squamous Cell Carcinoma?2021Annals of surgical oncology
  38. Letter to the Editor: Comparison of Outcomes Between Additional Esophagectomy After Noncurative Endoscopic Resection and Upfront Esophagectomy for T1N0 Esophageal Squamous Cell Carcinoma.2021Annals of surgical oncology
  39. Oncogenic enhancers drive esophageal squamous cell carcinogenesis and metastasis.2021Nature communications免费全文
  40. Long-term follow-up of a phase I/II trial of radiation dose escalation by simultaneous integrated boost for locally advanced esophageal squamous cell carcinoma.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
它在 ClinicalTrials.gov 上的全部试验(任何状态)31
  1. Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer正在招募NCT07811752牵头方II期2026-07 启动
  2. Infiltration Pattern of Locally Advanced ESCC邀请入组NCT07567716牵头方2025-10 启动
  3. RAE Versus MIE in Patients With Esophageal Cancer After Neoadjuvant Therapy即将招募NCT06012214牵头方不分期2024-01 启动
  4. A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)正在招募NCT06709417牵头方II期2024-11 启动
  5. Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)正在招募NCT06385730牵头方II期2024-06 启动
  6. Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial即将招募NCT06178211牵头方II期2023-12 启动
  7. Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma正在招募NCT05978193牵头方II期2023-01 启动
  8. Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer正在招募NCT06173986牵头方I/II期2023-01 启动
  9. Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma正在招募NCT04135664牵头方III期2019-09 启动
  10. Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)进行中,不再招募NCT05621707牵头方II期2022-11 启动
  11. Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC(NICE-RT)状态不明NCT05650216牵头方II期2022-12 启动
  12. Pre-Surgery If Needed for Oesophageal Cancer已完成NCT03937362牵头方2019-08 启动
  13. Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer状态不明NCT03913182牵头方II期2019-04 启动
  14. KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT03927495牵头方II期2019-05 启动
  15. Robot-assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy状态不明NCT03094351牵头方III期2017-07 启动
  16. Phase II Study of Neo-adjuvant Chemoradiotherapy for Squamous Cell Esophageal Cancer状态不明NCT02938195牵头方II期2016-01 启动
  17. Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer状态不明NCT02891083牵头方III期2016-01 启动
  18. SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy即将招募NCT07524374牵头方(推断)II期2026-03 启动
  19. Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC即将招募NCT06861894牵头方(推断)II期2025-07 启动
  20. Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma正在招募NCT06056336牵头方(推断)II期2023-09 启动
  21. Safety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma即将招募NCT06756841研究中心不分期2024-12 启动
  22. A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)正在招募NCT05319730研究中心I/II期2023-05 启动
  23. Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.进行中,不再招募NCT05043688研究中心III期2021-09 启动
  24. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  25. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  26. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  27. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)已完成NCT04210115研究中心III期2020-02 启动
  28. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  29. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  30. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)已完成NCT02649361研究中心II期2016-01 启动
  31. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma状态不明NCT01232374研究中心II期2010-09 启动
PubMed 以外找到的论文(未计入)56
  1. 107. CAMRELIZUMAB AND LOW-DOSE RADIOTHERAPY WITH CONCURRENT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (NICE-RT STUDY): PRELIMINARY RESULTS2025Diseases of the Esophagus论文
  2. 192. INDUCTION IMMUNOCHEMOTHERAPY FOLLOWED BY CONCURRENT CHEMORADIOTHERAPY FOR UNRESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (RICE): PRELIMINARY RESULTS2025Diseases of the Esophagus论文
  3. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncology论文
  4. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncology论文
  5. 273. LONG-TERM SURVIVAL AND TREATMENT PATTERNS IN RESECTABLE ESCC IN EAST ASIA: A COMPREHENSIVE STUDY FROM THE INTERNATIONAL ESODATA-STUDY-GROUP (DRAGON STUDY)2025Diseases of the Esophagus论文
  6. 290. OPTIMIZING ESOPHAGEAL CANCER TREATMENT: PERSONALIZED CTDNA IMPROVES RESIDUAL DISEASE DETECTION AFTER NEOADJUVANT CHEMORADIOTHERAPY AND GUIDES ADAPTIVE ADJUVANT IMMUNOTHERAPY2025Diseases of the Esophagus论文
  7. 379. HEALTH-RELATED QUALITY OF LIFE FOLLOWING ROBOTIC VERSUS THORACOSCOPIC ESOPHAGECTOMY: A PRESPECIFIED SECONDARY ANALYSIS OF THE MULTICENTER REVATE TRIAL2025Diseases of the Esophagus论文
  8. A Multi-Dimensional Deep Ensemble Learning Model Predicts Pathological Response and Treatment Outcomes to Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma Using Pretreatment CT Images: A Multicenter, Retrospective Cohort 2025International Journal of Radiation Oncology*Biology*Physics论文
  9. Abstract 1945: High-sensitive gastrointestinal cancers early detection by cell-free DNA targeted methylation sequencing with an innovative modeling approach2025Cancer Research会议摘要
  10. Abstract CT121: A phase 1/2a, multicenter, open-label, first in human study of a bispecific ADC targeting B7H3 and PDL1 (DB-1419) in advanced or metastatic solid tumors2025Cancer Research会议摘要
  11. Bufalin Suppresses Esophageal Squamous Cell Carcinoma Progression through Protein Arginine Methyltransferase-6/AKT/Mammalian Target of Rapamycin Pathway Inhibition2025World Journal of Traditional Chinese Medicine论文
  12. Neoadjuvant adebrelimab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: A phase 2 trial.2025Journal of Clinical Oncology会议摘要
  13. PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study2025Journal of Thoracic Oncology论文
  14. Radiotherapy as an Organ-Preserving Alternative to Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Achieving Major Pathologic Response after Induction Immunochemotherapy2025International Journal of Radiation Oncology*Biology*Physics论文
  15. WITHDRAWN: 261eP Methylation profiling to predict different recurrence pattern in esophageal cancer2025Annals of Oncology撤稿
  16. 317. PD-L1 DYNAMICS DURING THE CISPLATIN-INDUCED ACQUIRED RESISTANCE PROCESS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2024Diseases of the Esophagus论文
  17. 552. COMPARING ROBOTIC ESOPHAGECTOMY TO VIDEO-ASSISTED THORACOSCOPIC ESOPHAGECTOMY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: RESULTS FROM THE REVATE RANDOMIZED CLINICAL TRIAL2024Diseases of the Esophagus论文
  18. 560. ANALYSIS OF CLINICOPATHOLOGICAL CHARACTERISTICS AND PROGNOSIS OF SYNCHRONOUS MULTIPLE PRIMARY ESOPHAGEAL SQUAMOUS CELL CARCINOMAS (SMP-ESCC) AFTER RECEIVING NEOADJUVANT THERAPY2024Diseases of the Esophagus论文
  19. 571. A PHASE I/II MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF INDUCTION IMMUNOCHEMOTHERAPY FOLLOWED BY CONCURRENT IMMUNO-CHEMORADIOTHERAPY IN UNRESECTABLE LA-ESCC2024Diseases of the Esophagus论文
  20. 575. PATHOLOGIC RESPONSE AND RESIDUAL LYMPH NODE PATTERNS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS UNDERGOING NEOADJUVANT IMMUNOCHEMOTHERAPY COMPARED TO NEOADJUVANT CHEMORADIOTHERAPY2024Diseases of the Esophagus论文
  21. 582. LOW EXPRESSION OF FRG1 PROMOTES MIGRATION AND INVASION IN ESOPHAGEAL CANCER2024Diseases of the Esophagus论文
  22. Abstract 7646: Evaluation of tumor immune microenvironment after neoadjuvant immunotherapy in patients with esophageal squamous cell carcinoma (ESCC): Towards a prediction for recurrence risk2024Cancer Research会议摘要
  23. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): A prospective multicenter diagnostic cohort study in Asia.2024Journal of Clinical Oncology会议摘要
  24. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  25. Homologous recombination deficiency score served as an independent prognosis factor in esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  26. Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (RICE): A Prospective, Single-Arm, Phase II Trial2024International Journal of Radiation Oncology*Biology*Physics论文
  27. Interim results from a prospective multicenter phase II trial of stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC trial).2024Journal of Clinical Oncology会议摘要
  28. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Square预印本
  29. The feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): Update results of a retrospective exploratory study.2024Journal of Clinical Oncology会议摘要
  30. 190. PROGNOSTIC VALUE OF COMBINATION OF LYMPHOCYTE-TO-MONOCYTE-RATIO AND CYFRA 21-1 IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2023Diseases of the Esophagus论文
  31. 191. CIRCULATING TUMOR DNA (CTDNA) ANALYSIS FOR DETECTION OF RESIDUAL DISEASE AFTER NEOADJUVANT CHEMORADIOTHERAPY (NCRT) FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)2023Diseases of the Esophagus论文
  32. Exploration of Multiomic Profiles and Biomarkers as Predictors of Neoadjuvant Chemoradiotherapy Responsiveness in Esophageal Squamous Cell Carcinoma2023International Journal of Radiation Oncology*Biology*Physics论文
  33. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncology会议摘要
  34. P-162 Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): A retrospective exploratory study2023Annals of Oncology会议摘要
  35. Personalized circulating tumor DNA (ctDNA) analysis in predicting residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC).2023Journal of Clinical Oncology会议摘要
  36. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncology会议摘要
  37. 113P Brain metastases in esophageal cancer patients who have been treated with neoadjuvant immunotherapy plus chemotherapy: An inconsiderable complication2022Annals of Oncology论文
  38. 357. POSTOPERATIVE OUTCOMES OF SALVAGE ESOPHAGECTOMY AFTER DEFINITIVE CHEMORADIOTHERAPY AND PLANNED ESOPHAGECTOMY AFTER NEOADJUVANT CHEMORADIOTHERAPY2022Diseases of the Esophagus论文
  39. 371. MAPPING OF LYMPH NODE METASTASIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA AT ESOPHAGOGASTRIC JUNCTION: A RETROSPECTIVE SURGICAL STUDY COHORT2022Diseases of the Esophagus论文
  40. 508. OUTCOME OF NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN EAST ASIA VERSUS WESTERN EUROPE2022Diseases of the Esophagus论文
  41. 70P A retrospective real-world study of anlotinib plus PD-1 inhibitors in advanced esophageal squamous cell carcinoma (ESCC) previously treated with immune checkpoint inhibitors (ICIs)2022Immuno-Oncology Technology论文
  42. APEC: Efficacy and toxicity of anlotinib plus PD-1 inhibitors as later-line therapy in advanced/metastatic esophageal squamous cell carcinoma (ESCC): A retrospective real-world study.2022Journal of Clinical Oncology会议摘要
  43. Circulating tumor DNA (ctDNA) in predicting residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC).2022Journal of Clinical Oncology会议摘要
  44. First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.2022Journal of Clinical Oncology会议摘要
  45. Outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal squamous cell carcinoma in East Asia versus Western Europe2022European Journal of Surgical Oncology论文
  46. Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  47. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncology论文
  48. 70 IMPACT OF LYMPH NODE YIELD ON SURVIVAL IN PATIENTS UNDERGOING NEOADJUVANT CHEMORADIOTHERAPY FOLLOWED BY SURGERY FOR LOCALLY ADVANCED ESOPHAGEAL CANCER2021Diseases of the Esophagus论文
  49. A phase II study of neoadjuvant immunotherapy combined with chemotherapy (camrelizumab plus albumin paclitaxel and carboplatin) in resectable thoracic esophageal squamous cell cancer (NICE study): Interim results.2021Journal of Clinical Oncology会议摘要
  50. ASO Visual Abstract: Additional esophagectomy following noncurative endoscopic resection for early esophageal squamous cell carcinoma: a multicenter retrospective study2021Annals of Surgical Oncology论文
  51. ASO Visual Abstract: Occurrence and Prognostic Value of Perineural Invasion in Esophageal Squamous Cell Cancer: A Retrospective Study2021Annals of Surgical Oncology会议摘要
  52. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  53. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncology会议摘要
  54. Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.2021Journal of Clinical Oncology会议摘要
  55. Robot-Assisted Minimally Invasive Esophagectomy in China2021Springer eBooks书籍章节
  56. Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma2021Annals of Surgery论文

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年没有牵头骨肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

上海有 34 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
牵头的论文3
  1. Diagnosis of early idiopathic pulmonary fibrosis: current status and future perspective.2025Respiratory research
  2. The applications of CT with artificial intelligence in the prognostic model of idiopathic pulmonary fibrosis.2024Therapeutic advances in respiratory disease
  3. Clinical, radiologic, and physiologic features of idiopathic pulmonary fibrosis (IPF) with and without emphysema.2022Expert review of respiratory medicine
中文论文(未计入)1
  1. [Advances in predictive models for idiopathic pulmonary fibrosis].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis即将招募NCT07131150研究中心II期2025-08 启动
  2. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast进行中,不再招募NCT06238622研究中心III期2024-09 启动
  3. A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects已完成NCT05895565研究中心I期2023-05 启动
  4. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05938920研究中心II期2023-06 启动
  5. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05321069研究中心III期2022-10 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

上海市胸科医院

Shanghai Chest Hospital

上海

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University; Shanghai Red Cross Chest Hospital

提出更正下载数据